Individualizing therapy in acute coronary syndromes

Using a multiple biomarker approach for diagnosis, risk stratification, and guidance of therapy

Vivian Y. Mo, James A de Lemos

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Patients with non-ST-elevation acute coronary syndromes (ACS) are typically grouped together and treated with similar approaches to therapy despite tremendous variability in clinical presentation and prognosis. The cardiac troponins are biomarkers of myocardial necrosis that have recently been evaluated in conjunction with markers of neurohormonal activation such as brain natriuretic peptide, and markers of systemic inflammation such as C-reactive protein, to further characterize risk in the individual patient presenting with ACS. Measurement of biomarkers that reflect different components of the underlying pathophysiology appears to provide independent and complementary risk stratification information in patients with non-ST-elevation ACS. This review summarizes the rationale for a multimarker approach to risk stratification in ACS and also discusses other cardiac biomarkers under active investigation. One of these of particular interest is soluble CD40 ligand, a biomarker that may not only indicate active inflammation and platelet activation associated with ACS, but may also exhibit direct prothrombotic properties that mediate early atherogenesis, plaque rupture, and thrombosis.

Original languageEnglish (US)
Pages (from-to)273-278
Number of pages6
JournalCurrent Cardiology Reports
Volume6
Issue number4
StatePublished - Jul 2004

Fingerprint

Acute Coronary Syndrome
Biomarkers
Inflammation
Therapeutics
CD40 Ligand
Troponin
Brain Natriuretic Peptide
Platelet Activation
C-Reactive Protein
Rupture
Atherosclerosis
Thrombosis
Necrosis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{213a83aa316b45e1b5785cda866ba6e5,
title = "Individualizing therapy in acute coronary syndromes: Using a multiple biomarker approach for diagnosis, risk stratification, and guidance of therapy",
abstract = "Patients with non-ST-elevation acute coronary syndromes (ACS) are typically grouped together and treated with similar approaches to therapy despite tremendous variability in clinical presentation and prognosis. The cardiac troponins are biomarkers of myocardial necrosis that have recently been evaluated in conjunction with markers of neurohormonal activation such as brain natriuretic peptide, and markers of systemic inflammation such as C-reactive protein, to further characterize risk in the individual patient presenting with ACS. Measurement of biomarkers that reflect different components of the underlying pathophysiology appears to provide independent and complementary risk stratification information in patients with non-ST-elevation ACS. This review summarizes the rationale for a multimarker approach to risk stratification in ACS and also discusses other cardiac biomarkers under active investigation. One of these of particular interest is soluble CD40 ligand, a biomarker that may not only indicate active inflammation and platelet activation associated with ACS, but may also exhibit direct prothrombotic properties that mediate early atherogenesis, plaque rupture, and thrombosis.",
author = "Mo, {Vivian Y.} and {de Lemos}, {James A}",
year = "2004",
month = "7",
language = "English (US)",
volume = "6",
pages = "273--278",
journal = "Current Cardiology Reports",
issn = "1523-3782",
publisher = "Current Medicine Group",
number = "4",

}

TY - JOUR

T1 - Individualizing therapy in acute coronary syndromes

T2 - Using a multiple biomarker approach for diagnosis, risk stratification, and guidance of therapy

AU - Mo, Vivian Y.

AU - de Lemos, James A

PY - 2004/7

Y1 - 2004/7

N2 - Patients with non-ST-elevation acute coronary syndromes (ACS) are typically grouped together and treated with similar approaches to therapy despite tremendous variability in clinical presentation and prognosis. The cardiac troponins are biomarkers of myocardial necrosis that have recently been evaluated in conjunction with markers of neurohormonal activation such as brain natriuretic peptide, and markers of systemic inflammation such as C-reactive protein, to further characterize risk in the individual patient presenting with ACS. Measurement of biomarkers that reflect different components of the underlying pathophysiology appears to provide independent and complementary risk stratification information in patients with non-ST-elevation ACS. This review summarizes the rationale for a multimarker approach to risk stratification in ACS and also discusses other cardiac biomarkers under active investigation. One of these of particular interest is soluble CD40 ligand, a biomarker that may not only indicate active inflammation and platelet activation associated with ACS, but may also exhibit direct prothrombotic properties that mediate early atherogenesis, plaque rupture, and thrombosis.

AB - Patients with non-ST-elevation acute coronary syndromes (ACS) are typically grouped together and treated with similar approaches to therapy despite tremendous variability in clinical presentation and prognosis. The cardiac troponins are biomarkers of myocardial necrosis that have recently been evaluated in conjunction with markers of neurohormonal activation such as brain natriuretic peptide, and markers of systemic inflammation such as C-reactive protein, to further characterize risk in the individual patient presenting with ACS. Measurement of biomarkers that reflect different components of the underlying pathophysiology appears to provide independent and complementary risk stratification information in patients with non-ST-elevation ACS. This review summarizes the rationale for a multimarker approach to risk stratification in ACS and also discusses other cardiac biomarkers under active investigation. One of these of particular interest is soluble CD40 ligand, a biomarker that may not only indicate active inflammation and platelet activation associated with ACS, but may also exhibit direct prothrombotic properties that mediate early atherogenesis, plaque rupture, and thrombosis.

UR - http://www.scopus.com/inward/record.url?scp=5444225759&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=5444225759&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 273

EP - 278

JO - Current Cardiology Reports

JF - Current Cardiology Reports

SN - 1523-3782

IS - 4

ER -